Compare · NVO vs SGMT
NVO vs SGMT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sagimet Biosciences Inc. (SGMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SGMT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.38B, about 467.9x SGMT ($402.6M).
- Over the past year, NVO is down 46.8% and SGMT is up 9.9% - SGMT leads by 56.8 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 6 for SGMT).
- NVO has more recent analyst coverage (25 ratings vs 15 for SGMT).
- Company
- Novo Nordisk A/S
- Sagimet Biosciences Inc.
- Price
- $42.19+2.89%
- $6.52+0.00%
- Market cap
- $188.38B
- $402.6M
- 1M return
- -8.44%
- -15.16%
- 1Y return
- -46.83%
- +9.95%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 15
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SGMT
- Sagimet Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 4 filed by Chief Financial Officer Chauche Thierry
- SEC Form 4 filed by Chief Medical Officer Grauer Andreas
- SEC Form 4 filed by Chief Legal & Admin. Officer Rozek Elizabeth
- SEC Form 4 filed by President & CEO Happel David
- Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
- SEC Form 4 filed by Chief Medical Officer Grauer Andreas
- SEC Form 3 filed by new insider Grauer Andreas
- Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits